{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:51:19Z","timestamp":1792788679816,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Battelle Biomedical Research Center","id":[{"id":"https:\/\/ror.org\/0525ajp52","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Blood Centers of the Pacific","id":[{"id":"https:\/\/ror.org\/033tgbx59","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Interstate Blood Banks, Inc."},{"name":"List Biological Laboratories","id":[{"id":"https:\/\/ror.org\/02g7z3v47","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Travel and Immigration Clinic of Columbus"},{"name":"Cato Research Ltd."},{"name":"DynPort Vaccine Company LLC"},{"name":"Remington-Davis Clinical Research","id":[{"id":"https:\/\/ror.org\/05psy1s28","id-type":"ROR","asserted-by":"crossref"}]},{"name":"US Department of Defense Joint Vaccine Acquisition Program"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.vaccine.2018.02.042","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T11:06:58Z","timestamp":1519384018000},"page":"2041-2048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A\/B, in volunteers with pre-existing botulinum toxoid immunity"],"prefix":"10.1016","volume":"36","author":[{"given":"Jessica M.","family":"Khouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth N.","family":"Motter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Arnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.02.042_b0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1542\/peds.2006-0646","article-title":"Creation and development of the public service orphan drug Human Botulism Immune Globulin","volume":"119","author":"Arnon","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.02.042_b0010","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJMoa051926","article-title":"Human Botulism Immune Globulin for the treatment of infant botulism","volume":"354","author":"Arnon","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.02.042_b0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4161\/hv.9420","article-title":"Botulinum neurotoxin vaccines: past history and recent developments","volume":"5","author":"Rusnak","year":"2009","journal-title":"Hum Vacc"},{"key":"10.1016\/j.vaccine.2018.02.042_b0020","first-page":"1454","article-title":"Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.02.042_b0025","doi-asserted-by":"crossref","first-page":"D33","DOI":"10.1016\/j.vaccine.2009.08.059","article-title":"Botulism and vaccines for its prevention","volume":"27","author":"Smith","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2018.02.042_b0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/mds.20009","article-title":"Roads from vaccines to therapies","volume":"19","author":"Smith","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.vaccine.2018.02.042_b0035","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.vaccine.2012.01.035","article-title":"Preclinical safety assessment of recombinant botulinum vaccine A\/B (rBV A\/B)","volume":"30","author":"Shearer","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.042_b0040","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1016\/j.vaccine.2010.08.076","article-title":"Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A\/B)","volume":"28","author":"Shearer","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.042_b0045","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0041-0101(98)00146-9","article-title":"Development of recombinant vaccines for botulinum neurotoxin","volume":"36","author":"Smith","year":"1998","journal-title":"Toxicon"},{"key":"10.1016\/j.vaccine.2018.02.042_b0050","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1615\/CritRevImmunol.v27.i4.20","article-title":"Botulinum neurotoxin vaccines: past, present, and future","volume":"27","author":"Smith","year":"2007","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.02.042_b0055","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/CVI.00080-10","article-title":"Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1","volume":"17","author":"Sanford","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.02.042_b0060","doi-asserted-by":"crossref","first-page":"731604","DOI":"10.1155\/2012\/731604","article-title":"Advanced development of the rF1V and rBV A\/B vaccines: progress and challenges","volume":"2012","author":"Hart","year":"2012","journal-title":"Adv Prev Med"},{"key":"10.1016\/j.vaccine.2018.02.042_b0065","series-title":"Botulism in the United States, 1899\u20131996: handbook for epidemiologists, clinicians and laboratory workers","author":"Centers for Disease Control and Prevention","year":"1998"},{"key":"10.1016\/j.vaccine.2018.02.042_b0070","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/978-1-4613-0361-9_39","article-title":"Detection and identification of Clostridium botulinum neurotoxins","volume":"391","author":"Hatheway","year":"1996","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2018.02.042_b0075","series-title":"Proceedings of the symposium on botulism","first-page":"113","article-title":"Botulinum toxoids","author":"Cardella","year":"1964"},{"key":"10.1016\/j.vaccine.2018.02.042_b0080","series-title":"Therapy with botulinum toxin","first-page":"93","article-title":"Immunogenicity of the neurotoxins of Clostridium botulinum","author":"Hatheway","year":"1994"},{"key":"10.1016\/j.vaccine.2018.02.042_b0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2017.10.035","article-title":"Efficacy of Human Botulism Immune Globulin for the treatment of infant botulism: the first 12 years post licensure","volume":"193","author":"Payne","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2018.02.042_b0090","unstructured":"Centers for Disease Control and Prevention. National Botulism Surveillance. Available from: https:\/\/www.cdc.gov\/botulism\/surveillance.html [accessed 1\/31\/2018]."},{"key":"10.1016\/j.vaccine.2018.02.042_b0095","unstructured":"California Department of Public Health. Package Insert for BabyBIG [Botulism Immune Globulin Intravenous (Human) (BIG-IV)]; 2015. Available from: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/ucm117160.pdf [accessed 1\/31\/2018]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:25:03Z","timestamp":1759400703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18302160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":19,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0264410X18302160"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A\/B, in volunteers with pre-existing botulinum toxoid immunity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}